Food compositions containing punicalagins

FIELD: pharmacology.

SUBSTANCE: invention mainly relates to a food composition, including punicalagins.

EFFECT: improved action in respect to health improvement.

8 cl, 1 tbl, 1 ex

 

The technical FIELD

The present invention relates generally to food compositions comprising punicalagin, and to methods of use of such food compositions, including punicalagin.

DISCLOSURE of INVENTIONS

In one embodiment, the present invention is directed to a food composition comprising a protein source, a source of fat, a source of carbohydrates and punicalagin.

In another embodiment, the invention is directed to a method of strengthening the immune system of the child with the introduction of punicalagins.

Additionally, the invention, in one embodiment, is directed to a method of reducing allergic inflammatory reactions in the introduction of punicalagins.

The BEST WAY of carrying out the INVENTION

Next, we present the detailed embodiments of the invention, one or more examples of which will be disclosed below. Each example is for purposes of explanation of the invention and not for limitation. In fact, for the person skilled in the art should understand that various changes and variations can be made in this invention without departing from the essence and scope of the invention. For example, the features shown or described as part of one variant of implementation, can be used in another embodiment to policythese one additional option implementation.

Thus, it is understood that the present invention covers such modifications and variations which fall under the scope of the attached claims and their equivalents. Other objects, features and aspects of the present invention are disclosed or are obvious from the following detailed description. For the specialist in this area should be clear that the present discussion is a description of typical embodiments and are not intended to limit the broader aspects of the present invention.

The present invention relates, in some embodiments, implementation, to food compositions comprising a protein source, a source of fat, a source of carbohydrates and punicalagin. The food composition may be performed in any manner known in this area, such as a powder, gel, suspension, paste, solid form, liquid, liquid concentrate or ready to use. Food composition, in some embodiments, the implementation may include dietary Supplement product for baby food, the composition for infants, breast milk fortifier or any other food composition intended for children or infants. In the framework of the invention, the terms "children" or "child" refers to anyone aged from one to 13 years. In some embodiments, implementation of the program, the terms "children" or "child" refers to anyone aged two, three, four, five or six years. The term "product for baby food" means a composition that satisfies at least part of the diet of the child. In the framework of the invention, the term "child" means a person after birth at the age of less than approximately one year. The term "composition for infants" means a composition that satisfies the diet of the baby when replacing breast milk.

Punicalagin are tannins, large polyphenol compounds that are isomers of 2,3-(S)-hexahydrocannabinol-4,6-(S,S)-Gallager-D-glucose, hydrolyzable tannins with a molecular weight of 1084. Punicalagin are the predominant pomegranate tannins.

In some embodiments of the invention, punicalagin are present in the food composition in an amount constituting from about 0.004 to about 0.20 mg/g of the composition. In other embodiments of the invention punicalagin present in the amount of approximately 0,008 to approximately 0,12 mg/g of composition.

If the composition of the invention is administered to the infant or child, the amount of punicalagins can be from about 1 mg to about 100 mg per day. In other embodiments, the implementation of a number of punicalagins entered the infant or child with a composition according to the invention, the mod is et to be from about 5 mg to about 50 mg per day. In some embodiments, the implementation of a number of punicalagins entered the infant or child with a composition according to the invention can be from about 10 mg to about 35 mg per day.

In some embodiments, implementation of the food composition of the present invention further includes panicaway (pomegranate) acid. Panikova acid is a polyunsaturated fatty acid, 18:3 (n-5). She received oil from seeds of the pomegranate. Its chemical formula C18H30O2. Panikova acid is conjugated linoleic acid. It has three conjugated double bonds, and it is chemically similar to conjugated linoleic acid, which are two of them.

The term "panikova acid", in the framework of the invention, refers to a paired isomer of linolenic acid, CIS-9, TRANS-11, CIS-13 double bond in the C18-carbon chain, its non-toxic salts, active esters, active isomers, active metabolites, structural lipids containing panicaway acid, and their mixtures.

In some embodiments of the invention, panikova acid is present in amount of about 0.01 to about 40 mg/g of the composition. In additional embodiments of the invention panikova acid is present in a quantity sostavlyajushie is from about 0.02 to about 20 mg/g of composition.

If the composition according to the invention is administered to an infant or child, the number of input panicaway acid can be from about 25 mg to about 10 g per day. In additional embodiments, the implementation of a number panicaway acid introduced to the infant or child with a composition according to the invention can be from about 50 mg to about 5 g per day.

If panikova acid added to the food composition according to the present invention, the mass ratio punicalagin:panikova acid may be from about 1:10000 to about 4:1. In some embodiments, implementation of the present invention, the mass ratio punicalagin:panikova acid may be from about 1:1000 to about 1:1. In additional embodiments, the implementation ratio can be from about 1:500 to about 2:3.

In additional embodiments of the invention, the food composition may additionally include a leaf extract of pomegranate. Although previous studies were mainly concerned with the fruits of pomegranate leaf extract of pomegranate can also bring health benefits. Application of leaf extract of pomegranate in combination with punicalagin in accordance with the present invention may have an additional positive effect is t on the health of infants, children and adult mammals.

In some embodiments of the invention, the extract of pomegranate leaves is present in amount of about 4 mg/g to about 60 mg/g of the composition. In additional embodiments of the invention the extract of pomegranate leaves is present in amount of about 12 mg/g to about 48 mg/g of composition.

If the composition of the invention are introduced to the infant or child, then enter the number of leaf extract of pomegranate can be from about 1 g to about 15 g per day. In additional embodiments, the implementation of a number of leaf extract of pomegranate, enter the infant or child with a composition according to the invention can range from about 3 g to about 12 g per day. In some embodiments, the implementation of a number of leaf extract of pomegranate, enter the infant or child with a composition according to the invention can be from about 5 g to about 10 g per day.

If the food composition comprises the extract of the leaves of the pomegranate, the mass ratio punicalagin:leaf extract of pomegranate can be from about 1:15,000 to about 1:100. In some embodiments, implementation of the present invention, the mass ratio of punicalagins:leaf extract gr is Nata can be from about 1:2400 to about 1:60. In additional embodiments, the implementation ratio can be from about 1:500 to about 1:10.

In additional embodiments, the implementation in the food compositions of the present invention punicalagin can be used together with panicaway acid and leaf extract of pomegranate. The combination of punicalagins, panicaway acid and extract of the leaves of the pomegranate may have an additional positive impact on the health of infants, children and adults mammalian subjects.

If punicalagin included in the composition for infants or product for baby food, such composition or product can fully meet the diet and may contain appropriate types and amounts of lipids, carbohydrates, proteins, vitamins and minerals. In the framework of the invention, the term "fully satisfies the diet" refers to a food composition, which can be used as the sole source of food, which provides the subject of the required daily intake of vitamins, minerals and/or trace elements in combination with proteins, carbohydrates and lipids.

If the composition of the present invention is a composition for infants, the amount of lipids or fats in the composition for infants can vary from about 3 to about 7 g/100 kcal. As sources of l is pidof can be any known in the field, for example, vegetable oils such as palm oil, canola oil, corn oil, soybean oil, palmolein, coconut oil, oil triglycerides with medium chain length, sunflower oil with high oleic acid safflower oil high oleic acid, fish oil, etc., the Amount of carbohydrate can vary from about 8 to about 12 g/100 kcal. As sources of carbohydrates can be any known in this field, for example lactose, dextrose, dried corn syrup, maltodextrins, sucrose, starch, dry rice syrup, etc.,

The amount of protein, if the present composition is a composition for infants, can vary from about 1 to about 5 g/100 kcal. As sources of protein can be any known in the field, such as skim milk, whey protein, casein, soy protein, hydrolyzed protein, amino acids, etc. In a specific embodiment, the protein source contains bovine serum and bovine casein. In one embodiment, the serum can be a concentrate denatured whey protein. In another embodiment, the serum can be a concentrate, Undenatured milk protein is whey. In a specific embodiment, the protein source may contain both denatured and Undenatured protein concentrate whey.

If the composition of the present invention is a composition for babies, suitable examples of formulations for infants may include the following: soy-based, partially or fully hydrolyzed, lactose free, low lactose, elementary, protein-free, anti-regurgitation, for premature or standard formulations for babies. The type of compound for babies can be chosen based on the condition of the infant, to ensure proper digestion and healthy condition.

The composition of the present invention is suitable for both full-term and premature infants. As a result, if the composition of the present invention is a composition for infants, the infant may be a composition for full-term or preterm infants. Similarly, if the composition of the present invention is a supplementation of breast milk, the breast milk fortifier may be a breast milk fortifier for full-term babies or supplementation of breast milk for preterm infants.

It was shown that long-chain polyunsaturated fatty acids (CPUFA) are important for the development of babies. Especially important are arachidonic acid (ARA; C20:4, n-6) and docosahexaenoic acid (DHA; C22:6 n-3) due to high concentrations of each detected in the brain and retina babies. ARA and DHA are synthesized from their 18-carbon precursors, respectively, linoleic acid (18:2, n-6) and α-linolenic acid (18:3, n-3) by the formation of alternating unsaturated bonds and lengthening. DHA and ARA, as a rule, go to breastfed infants through breast milk. However, for infants fed formula should include DHA and ARA in the diet.

There is evidence that infants with modified concentrations of LCPUFA, which is the result of an inadequate intake of dietary LCPUFA, may be at risk of neurological problems, may show poor performance in cognitive tests and have reduced the development of the retina compared with infants fed breast milk. Thus, the inclusion of LCPUFA, particularly ARA and DHA, in a quantity close to the content in human milk, can promote normal growth and neurological development of the mixture fed infants. Thus, in some embodiments of the invention, the food composition contains at least one LCPUFA. In a specific embodiment, the food composition comprises DHA and/or ARA.

Mass soo is wearing ARA:DHA, if included in the food composition may be from about 1:3 to about 9:1. In one embodiment of the present invention, this ratio is from about 1:2 to about 4:1. In yet another embodiment, the ratio is from about 2:3 to about 2:1. In one particular embodiment, the ratio is approximately 2:1. In another specific embodiment of the invention the ratio is approximately 1:1,5. In other embodiments, the implementation ratio is approximately 1:1,3. In other embodiments, the implementation ratio is approximately 1:1,9. In a specific embodiment, the ratio is approximately 1.5:1. In an additional embodiment, the ratio is approximately 1,47:1.

If DHA is included in the invention, the concentration of DHA may be approximately between 0.0% and 1.00% of the fatty acids by weight. In other embodiments, the implementation of the concentration of DHA may be approximately 0.32 per cent by weight. In some embodiments, the implementation of the concentration of DHA may be about 0.33 percent by weight. In another embodiment, the concentration of DHA may be approximately 0,64% by weight. In another embodiment, the concentration of DHA m which may equal approximately to 0.67% by weight. In yet another embodiment, the concentration of DHA may be about to 0.96% by weight. In an additional embodiment, the concentration of DHA may be about to 1.00% by mass.

If ARA is included in the invention, the concentration of ARA may be between 0.0% and 0.67% of the fatty acids by weight. In another embodiment, the concentration of ARA may be approximately 0,67% by weight. In another embodiment, the concentration of ARA may be approximately 0.5% by weight. In yet another embodiment, the concentration of DHA may be approximately between 0,47% 0,48% by mass.

In the present invention, the amount of DHA, if used, may be from about 2 mg/100 kilocalories (kcal) to approximately 100 mg/100 kcal. In another embodiment, the amount of DHA may be from about 5 mg/100 kcal to about 75 mg/100 kcal. In yet another embodiment, the amount of DHA may be from about 15 mg/100 kcal to about 60 mg/100 kcal.

In the present invention, the amount of ARA, if used, may be from about 4 mg/100 kilocalories (kcal) to approximately 100 mg/100 kcal. In another embodiment, the amount of ARA may be from about 10 mg/100 kcal to about 67 mg/100 kcal. Even on the nom embodiment, the amount of ARA may be from about 20 mg/100 kcal to about 50 mg/100 kcal. In a specific embodiment, the amount of ARA may be from about 25 mg/100 kcal to about 40 mg/100 kcal. In one embodiment, the amount of ARA is approximately 30 mg/100 kcal.

If the composition according to the invention further includes oils containing DHA and/or ARA, this can be accomplished by conventional methods known in this field. For example, an equivalent amount of oil, which usually is present in the composition, may be substituted DHA and/or ARA.

As the source of one or more LCPUFA, if used, may be any source known in this field, such as the fat of marine life, fish oil, oil unicellular, egg yolk lipids, the lipids of the brain, etc. Any LCPUFA can be in a natural form, provided that the remaining substance of the source of LCPUFA not result in significant adverse effects on the infant or child. Alternatively, LCPUFA can be used in purified form.

The source of LCPUFA, if used, may contain or may not contain eykozapentaenovuyu acid (EPA). In some embodiments, implementation specifically for feeding babies LCPUFA used in the invention does not contain or contains a small number of EPA. For example, in some embodiments, implementation of the food composition used C the ect, contain less than about 20 mg/100 kcal EPA; in some embodiments, the implementation of less than about 10 mg/100 kcal EPA; in other embodiments, the implementation of less than about 5 mg/100 kcal EPA; and in some other embodiments, implementation of essentially does not contain EPA.

In some embodiments of the invention, the food composition contains additional components, which may include probiotics or prebiotics. The term "probiotic" means a microorganism that has a beneficial effect on the health of the host. Any known in the field of probiotics can be added, forming an appropriate combination with other components of the composition. For example, the probiotic may be selected from the group consisting ofLactobacillusandBifidobacterium. Alternatively, the probiotic may beLactobacillus rhamnosusGG.

In some embodiments, implementation of the food composition of the present invention further includes at least one prebiotic. The term "prebiotic", in the framework of the invention, means nevereverever component of the food product, which stimulates the growth and/or activity of probiotics. In this embodiment, any known in the field of prebiotic can be added, forming an appropriate combination with other components of the composition. In Conques is enom embodiment, the prebiotic may be selected from the group consisting of fructooligosaccharide, inulin, glucooligosaccharide, galactooligosaccharide, isomaltooligosaccharide, xylooligosaccharide, soybean oligosaccharides, hotelyoshkarola, gentiopicroside, mannooligosaccharide, lactulose, lactosucrose, raffinose, arabinopyranoside, glucans, sialyloligosaccharide, Polydextrose, inulin, frukooligosaharidov and mixtures thereof.

In some embodiments, the implementation, the use of punicalagins alone or in combination with panicaway acid or leaf extract of pomegranate, or a combination of all three improves the development and function of immune system in children. For example, the use of punicalagins alone or in combination with panicaway acid or leaf extract of pomegranate, or a combination of all three may enhance resistance to infection and/or reduce the allergic inflammatory response, without limitation including asthma, wheezing, allergic cough, bronchiolitis, bronchitis and eczema. Thus, in some embodiments, the implementation, the invention relates to a method of enhancing the immune response of the child, including the introduction of the baby food composition of the present invention. In additional embodiments, the implementation, the invention relates to a method of enhancing the resistance to infection in a child, including the introduction of baby p. the food composition of the present invention. In other embodiments, the implementation, the invention relates to a method of reducing allergic inflammatory reactions in children, including the introduction of the baby food composition of the present invention. In the framework of the invention, the term "child" refers to people aged less than 13 years. In some embodiments, the implementation of the term "child" refers to people aged less than 8 years.

Additionally, in some embodiments, the implementation, the use of punicalagins alone or in combination with panicaway acid or leaf extract of pomegranate, or a combination of all three can contribute to the improvement of the cardiovascular system, eyes, development and brain function, condition and function of the gastrointestinal tract. Additionally, the use of punicalagins alone or in combination with panicaway acid or leaf extract of pomegranate, or a combination of all three can contribute to reducing the risk of inflammation, cancer or metabolic syndrome, including obesity and diabetes. Thus, in some embodiments, the implementation, the invention relates to a method for improving the state of the cardiovascular system and eyes of the child by introducing baby food composition of the present invention. In additional embodiments, the implementation, the invention relates to a method of improving the development and function of m is ZGA child by introducing baby food composition of the present invention. In other embodiments, the implementation, the invention relates to a method of improving the status and function of the gastrointestinal tract of the child by introducing baby food composition of the present invention. Such a variant embodiment of the invention may include the formation of a healthy balanced intestinal microflora in children. In some embodiments implementing the invention relates to a method of reducing the risk of inflammation and cancer the child by introducing baby food composition of the present invention. In additional embodiments implementing the invention relates to a method of reducing the risk of metabolic syndrome in a child by introducing baby food composition of the present invention. In this embodiment, reducing the risk of metabolic syndrome in children may include reducing the risk of obesity and diabetes.

In some embodiments, the implement, the combination of punicalagin with panicaway acid or with leaf extract of pomegranate or a combination of all three provides improved action in relation to health promotion as defined above. It is assumed that the activity of the combination of punicalagin with panicaway acid or with leaf extract of pomegranate, or a combination of all three above expected total activity with the introduction of each connection separately.

the Following example describes an implementation option of the present invention. Other embodiments of the amount of the claims will be apparent to the person skilled in the art based on the description or embodiment of the invention disclosed here. It is assumed that the description together with the sample covers only typical embodiments of, and scope of the invention defined in the claims that follows the example.

Example 1

Table 1 shows the nutritional components of a variant of implementation of the food composition composition for babies of the present invention.

Table 1
(Normal dilution)At 100 calories
(5 fluid oz)
100 grams powder
Proteins, g2,110,8
Fat, g5,327
Linoleic acid mg8604400
Linolenic acid mg85440
DHA, mg1788
ARA, mg34175
Hydrocarbons mg10,956
Water mg1343,3
Punicalagin mg1,910
Vitamins and Other nutrients
Vitamin a, IU3001550
Vitamin D, IU60310
Vitamin E, IU210,3
Vitamin K, mcg841
Thiamine (Vitamin B1), mcg80410
Riboflavin (Vitamin B2), mcg140720
Vitamin B6, mcg60310
Vitamin B12, mcg0,31,55
Niacin, mcg10005200
Folic acid (Folacin), mcg1683
Pantothenic acid, mcg5002600
Biotin, mcg315,5
Vitamin C (Ascorbic acid), mg1262
Choline, mg24124
Inositol, mg631
Carnitine, mg210,3
Taurine, mg631
Minerals
Calcium, mg78400
Phosphorus mg43220
Magnesium, mg841
Iron mg1,89,3
Zinc mg15,2
Manganese, mg1577
Copper mg75390
Iodine mg1052
Selenium mg2,814,5
Sodium, mg27139
Potassium, mg108560
Chloride, mg63330
The molybdenum mgn/an/a
Chromium, mgn/an/a

All references in this description, without limitation, include all documents, publications, patents, patent applications, presentations, texts, reports, manuscripts, brochures, books, posted online messages, articles in journals, periodic the definition of publication and so on, included in this description by reference in its entirety. Discussion of cited documents here as conclusions on the assertions made by their authors, and one should not treat any link as a component of the prior art. Applicants reserve the right to dispute the accuracy and relevance of these documents.

These and other modifications and changes of the present invention can be carried out by a person skilled in the art, without going beyond the scope of the present invention, more specifically articulated in the attached claims. In addition, it is understood that aspects of the various embodiments can be provided fully or partially. In addition, experts in this field should understand that the foregoing description is only an example and is not intended to limit the invention disclosed hereinafter in the appended claims. Therefore, the scope of the attached claims should not be limited by the description of the preferred options contained therein.

1. Food composition, including:
a) a protein source;
b) a source of fat;
c) a source of carbohydrates; and
d) punicalagin.

2. Food composition under item 1, where the number of punicalagin in the composition is from about 0.004 to about 0.20 mg/g of composition.

3.Food composition under item 1, additionally comprising panicaway acid.

4. Food composition under item 3, where the number panicaway acid in the composition is from about 0.01 to about 40 mg/g of composition.

5. Food composition under item 1, further comprising the leaf extract of pomegranate.

6. Food composition under item 5, where the number of leaf extract of pomegranate in the composition is from about 4 mg/g to about 60 mg/g of composition.

7. Food composition under item 1, further comprising panicaway acid and the extract of the leaves of the pomegranate.

8. Food composition on p. 1 wherein the food composition is a composition for babies.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microbiology. What is presented is using the strain Bifidobacterium longum NCC 2705 (CNCM-I2618) for preparing a complete nutrient composition used for relieving symptoms of allergy to food in the patients suffering allergies caused by ingestant allergens.

EFFECT: composition provides the secondary prevention of allergic reactions caused by the above ingestant allergens.

16 cl, 7 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to complex injection preparation for treating polynoses by ASIT method. Said preparation is obtained by simple mixing birch pollen allergoid and muramylpeptide without carrying out chemical conjugation of components, with 2 mg of muramylpeptide being added per 1000 PNU dose.

EFFECT: invention provides considerable enhancement of immune response and stimulates high level of production of specific IgG-antibodies, as well as makes it possible to reduce course of treatment of polynoses, which reduces possibility of complications.

1 dwg, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents composition for reducing injury caused by ultraviolet radiation, which includes one or more compounds selected from the group consisting of D-methionine and its salts.

EFFECT: invention provides creation of stable and safe composition, which can be applied daily.

10 cl, 37 ex, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and medicine, namely to manufacturing drug preparations for treating allergic diseases, such as allergic rhinitis and urticaria. According to the first version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including citric acid, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, starch, lactose, magnesium stearate, and talc. According to the second version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including Pearlitol 100SD-Mannitol, calcium hydrogen phosphate dihydrate, microcrystalline cellulose, starch, magnesium stearate, and talc. According to the third version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including sodium carboxymethyl starch, microcrystalline cellulose, colloidal silicone dioxide, and sodium sodium stearyl fumarate. According to the fourth version, the pharmaceutical composition contains an active substance that is desloratadine, and additives, including sodium carboxymethyl starch, microcrystalline cellulose, Pearlitol 100SD-Mannitol, magnesium stearate, and talc. The pharmaceutical composition is presented in the form of a film-coated tablet.

EFFECT: pharmaceutical composition according to the invention is storage-stable and releases the active substance quickly in the gastrointestinal tract.

10 cl, 9 tbl, 20 ex

FIELD: food industry.

SUBSTANCE: invention relates to nutritional compositions based on a natural extract. One proposes the application of an apple extract containing polyphenols for the manufacture of a complete nutritional composition for the reduction of symptoms of allergy caused by food in patients suffering from allergy caused by food allergens. The apple extract is enriched with polyphenols by at least 1.5 times relative to the unpurified apple extract. The composition contains 0.1% - 1 wt % of the apple extract.

EFFECT: proposed composition has no effect on the patients` sensitisation to the said allergens.

13 cl, 6 dwg

FIELD: biotechnology.

SUBSTANCE: invention is a composition having antibacterial, immunostimulating, anti-allergic and anti-inflammatory action, containing bacterial waste products useful for human body, in the form of exometabolites and fermentolysis products, characterised in that it is a culture medium of lactic acid bacteria, containing laxarane in an amount of 5-10 g/ml, caseicyne, isracydine or their mixture and lectins in an amount of 0.05-2.5 mol/l, histamine in an amount of 0.8-2.0 mmol/l and monocarboxylic fatty acid with an unbranched chain, namely, acetic acid, propionic acid, butyric acid and valeric acid - in an amount of 10-20 mg/ml.

EFFECT: expanding the range of agents having complementary antibacterial, immunomodulating, anti-allergic and anti-inflammatory action.

4 cl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of cosmetology. Described is a stable and safe antioxidant composition, which can be applied daily. In particular, described is the antioxidant composition, which contains one or more compounds, selected from the group, which consists of D-aspartic acid, its derivatives and/or its salts. The composition can be applied with the purpose of suppressing and/or relief of a skin condition. Conditions of skin can include, but are not limited by them, small wrinkles, rough skin, dry skin, skin cancer, skin allergy, skin inflammation, and light-sensitive dermatosis. The composition can be applied as a medication for the external application on the skin.

EFFECT: invention ensures an increase of the antioxidant effect of the composition.

4 cl, 5 dwg, 31 ex

FIELD: medicine.

SUBSTANCE: enterosorbent is administered in the morning in an S daily dose on an empty stomach daily for 1-3 months 2-3 hours before meals. Colonising the intestinal flora with a normal flora is ensured by daily 4-week roal administration of the liquid biocomplex Normoflorin 3 times a day in age doses; the first and second intakes involve the preparation Normoflorin L, and the third one - Normoflorin B.

EFFECT: effective treatment of allergic diseases by eliminating endogenous and exogenous toxic substances of various nature and reducing thereby body sensibilisation, providing extensive cleansing of the bowels from fermentation and putrifaction products, pathogenic and opportunistic flora, and ensuring natural immunity stimulation.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with application of extract of above-ground part/parts of oats, excluding grains, containing from 2 to 15% of flavonoids and from 0.2 to 2% of A and B avenacosides, for preparation of cosmetic and dermatological composition.

EFFECT: invention represents dermatological and cosmetic composition, containing such extract and possessing hypoallergenic properties.

8 cl, 2 ex, 2 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry and represents application of a composition, containing Bifidobacterium breve CNCM I-3865 (NCC2950) for preparation of a composition for prevention of allergic diarrhoea.

EFFECT: invention provides extension of an arsenal of means for prevention of allergic diarrhea.

7 cl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of organic chemistry, namely to heterocyclic compound of general formula (I) or to its pharmaceutically acceptable salt, acid salt or stereoisomer, where Y: NRa and N+R1R2X-; Z: bond, -(CH2)p, -CHOH, -CH=CH-, -C≡C-, -CONH- and -CO-; Rb: C1-C8 alkyl, C2-C8 alkenyl, C6-C10 aryl, -NR5R6,: , and ; with each alkyl, alkenyl and aryl, representing Rb, possibly, contains 1-3 substituents, selected from C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6- and 7-membered heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, halogen, -OH, -NH2, -CN and -NO2; Rc: halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, 9- and 10-membered bicyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; with C1-C6 alkyl, C2-C6 alkenyl C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C6-C10aryl, 5-, 6-, 7-, 8-membered monocyclic heterocyclyl and 9- and 10-membered bicyclic heterocyclyl, representing Rc, possibly contain 1-5 substituents, selected from the group, consisting of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C6 cycloalkyl, C4-C8 cycloalkenyla, halogen, -OH, -NH2, C6-C10 (A)(A')(A")(A'")aryl, (A)(A')(A")(A'")heterocyclyl, containing 1-3 heteroatom, selected from nitrogen, oxygen and sulphur, NR14R15, (CH2)pNR14R15, -CN, -NO2, oxo, -COOR14, SOR14, SO2R14, SO2NR14R15, NR15SO2R16, COR14, CONR14R15 and NR15COR16; with each (A), (A'), (A") and (A'")independently absent or representing C1-C4 alkyl, and each heterocyclyl (A)(A')(A")(A'")heterocyclyl is independently selected from the group, consisting of 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, and 9- and 10-membered bicyclico heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; the remaining radicals have values given in i.1;and on condition that, if Rc represents heterocyclyl, said heterocyclyl is bound directly through carbon atom of heterocyclyl ring. Invention also relates to particular compounds and to pharmaceutical composition based on formula (I) compound.

EFFECT: obtained are novel imidazopyrazine and imidazodiazepine derivatives, useful for prevention or treatment of disease or condition, severity of which is reduced by receptors to cannabinoids.

21 cl, 5 dwg, 4 tbl, 71 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to isoxazoline FAAH inhibitors of formula (I) or their pharmaceutically acceptable forms, wherein each of G, Ra, Rb, Rc and Rd has a value described in the present application, to pharmaceutical compositions, and methods of treating a FAAH-mediated condition.

EFFECT: developing the method of treating the FAAH-mediated condition.

32 cl, 22 tbl, 351 ex

FIELD: medicine.

SUBSTANCE: immunocorrective agent for the therapy of atherosclerotic diseases containing hawthorn blossom, common St. John's wort herb, as well as calcium stearate and silicone oxide taken in certain proportions.

EFFECT: agent is effective for the therapy of atherosclerotic diseases.

8 ex

FIELD: biotechnology.

SUBSTANCE: invention is a composition having antibacterial, immunostimulating, anti-allergic and anti-inflammatory action, containing bacterial waste products useful for human body, in the form of exometabolites and fermentolysis products, characterised in that it is a culture medium of lactic acid bacteria, containing laxarane in an amount of 5-10 g/ml, caseicyne, isracydine or their mixture and lectins in an amount of 0.05-2.5 mol/l, histamine in an amount of 0.8-2.0 mmol/l and monocarboxylic fatty acid with an unbranched chain, namely, acetic acid, propionic acid, butyric acid and valeric acid - in an amount of 10-20 mg/ml.

EFFECT: expanding the range of agents having complementary antibacterial, immunomodulating, anti-allergic and anti-inflammatory action.

4 cl, 5 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises giving to calves to drink the tincture of the combination herbal medicinal product - the grass of St. John's wort, meadowsweet, common yarrow, common nettle, rhizome of leather bergenia, root and rhizome of marsh cinquefoil, Scotch pine needles. At that the tincture fermented with microorganisms "EM Kurung" is used. The tincture is prepared by mixing 200 ml the tincture of the combination herbal medicinal product with 40 ml of the finished product "EM Kurung" and maintaining at the temperature of 18-20°C during the day, followed by filtration. EM-preparation "Baikal EM 1" is given to dry cows for 30 days prior to calving as a single dose in a dose of 30 ml/head. Mixoferon, sedimin and nitamin are additionally prescribed to new-born calves according to the following schedule: from the second feeding the tincture of the combination herbal medicinal product is watered with colostrum, fermented with microorganisms of EM-preparation "EM Kurung" at a dose of 150 ml/head dualfold for 10 days. On the 1, 2 and 8 day of life, mixoferon is injected intramuscularly at a dose of 9 ml/head. On the 1 and 8 day of life - nitamin and sedimin at a dose of 4 ml/head.

EFFECT: use of the claimed method enables to increase the immunobiological reactivity, energy of growth, provides prevention of gastrointestinal diseases of new-born calves.

4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: pathogenetic treatment of chronic tonsillitis and/or hypertrophy of palatine tonsils in preschool children suffering from lymphoproliferative syndrome is ensured by the palatine tonsils debridement. An interleukin-1β(IL-1β) level is measured in the palatine tonsils washing. If the measured value is less than 5.8 pg/ml, recombinant interleukin-1β (IL-1β) is to be administered orally by phonophoresis with the use of the Tonsillor MM apparatus. Two courses of 10 procedures every 14 days are performed. The clinical effectiveness is assessed if observing a positive dynamics of IL-1β measured in the palatine tonsils washing 17 and 41 days after the beginning of the immunomodulatory therapy.

EFFECT: higher clinical effectiveness ensured by the differentiated selection of children for carrying out the immunomodulatory therapy, reducing a rate of infectious involvements of the palatine tonsils in the declared group of patients by the pathogenetically reasoned application of recombinant IL-1β.

3 cl, 2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to biotechnology and represents a pharmaceutical composition applicable for treating a rheumatic disease and containing the humanised anti-CD4 antibody able to activate CD4+CD25+ regulatory T-cells, and methotrexat. The present invention also discloses a kit and a method of treating the rheumatic disease with using the above pharmaceutical combination and the above kit.

EFFECT: invention enables implementing more effective methods of treating the rheumatic diseases, including rheumatoid arthritis.

57 cl, 8 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and concerns treating the patients suffering oncological diseases by administering the preparations inducing active cellular immune stimulation. The preparations are administered in the form of lyophilised lysate of gram-positive enteric bacteria enclosed in gelatine capsules. That is combined with correcting intestinal dysbacteriosis, administering antioxidants, vitamins and minerals, as well as nutrient-enriched protein food, amino acid L-arginine, and pectin- and fibre-enriched vegetable food.

EFFECT: method provides higher clinical effectiveness of the patients suffering the oncological diseases with no side effects.

4 ex

FIELD: medicine.

SUBSTANCE: developed agent contains trophoblastic β-1-glycoprotein (TBG), immunoglobulin (Ig) and additionally contains tetrapeptide H-Tyr-X-Y-Glu-OH, wherein X - Gln and/or Glu, Y - Cys (acm) and/or Cys.

EFFECT: effective treatment of autoimmune diseases by single doses containing TBG 1 mg, Ig 19 mg and tetrapeptide 20 mg.

6 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to veterinary science and aims at normalising metabolic processes, stimulating immune system and blocking mechanisms of infectious process with a risk of endogenous infection activation. A method for producing a combination immunometabolic preparation with anti-infectious activity involves dissolving succinic acid and levamisole in demineralised water with formalin added. According to the other aspect of the invention, the immunometabolic preparation additionally contains polyethylene glycol. The ingredients are used in the declared ratio.

EFFECT: using this group of inventions provides producing an injection form of the immunometabolic preparation with anti-infectious activity.

2 cl, 3 tbl

FIELD: medicine.

SUBSTANCE: method for preparing an agent possessing anti-inflammatory, diuretic and antioxidant activity, involving milling Spiraea salicifolia shoots representing a mixture of leaves, blossom and shoots, extracting them three times by gradual maceration, mixing in infusing, filtering, condensing, separating, drying in the certain environment.

EFFECT: agent shoes the pronounced anti-inflammatory, diuretic and antioxidant activity.

2 dwg, 12 tbl

Up!